Cantor Fitzgerald Forecasts MiMedx Group FY2025 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of MiMedx Group in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of $0.33 for the year. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.05 by $0.02. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $84.06 million for the quarter, compared to analysts’ expectations of $81.00 million. During the same quarter last year, the company posted $0.05 earnings per share.

Separately, StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Price Performance

Shares of MDXG opened at $9.14 on Wednesday. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $10.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of 16.62 and a beta of 1.96. The stock has a 50 day moving average of $9.19 and a 200-day moving average of $7.43.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MDXG. Blue Trust Inc. bought a new stake in MiMedx Group in the third quarter valued at $30,000. Point72 Asset Management L.P. bought a new stake in MiMedx Group in the 2nd quarter valued at about $40,000. Point72 DIFC Ltd boosted its stake in MiMedx Group by 127.6% during the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after purchasing an additional 4,275 shares during the period. Entropy Technologies LP bought a new position in MiMedx Group in the 3rd quarter worth about $64,000. Finally, Orion Capital Management LLC increased its stake in shares of MiMedx Group by 46.3% in the third quarter. Orion Capital Management LLC now owns 11,700 shares of the company’s stock valued at $69,000 after purchasing an additional 3,700 shares during the period. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.